Immune therapy may be an alternate therapeutic approach for treating chronic hepatitis B

Hepatitis B virus (HBV) infection is global in nature and induces several incredible liver diseases, such as chronic hepatitis B (CHB), cirrhosis of the liver (LC) and hepatocellular carcinoma (HCC). A total of 882,000 patients died of HBV-related liver diseases in 2019.

This large number of deaths and HBV morbidity can be contained if patients with CHB are provided with proper management strategies. Currently, two varieties of antiviral drugs are approved for the treatment of CHB patients. However, the outcome of treatment with these antiviral drugs is neither rationally satisfactory nor patient-friendly. These drugs come with major limitations, such as cost, infinite usage, adverse effects, and low efficacy.

On the basis of the retrieved information, it seems that immune therapy may be an alternate therapeutic approach for treating CHB patients. In this article, it is shown why antiviral drugs and innovative antiviral compounds have limited roles in the treatment of CHB patients. On the other hand, the scope of immune therapies has been rationalized by providing scientific evidence and analyzing the mechanism of action of CHB. Therefore, various immune therapy designs have been proposed for treating CHB patients.